Brainsway - The New Paradigm for Brain Disorder Treatment

Brainsway’s Deep Transcranial Magnetic Stimulation (Deep TMS) revolutionizes the treatment of brain disorders by providing a non-invasive therapy that allows patients with Major Depressive Disorder (MDD) and other brain disorders to regain wellbeing, calm and happiness within just a few weeks.

Brainsway has created a strong clinical platform by partnering with several renowned research facilities. One ofBrainsway’s key differentiators is that Deep TMS is a non-invasive treatment with no systemic side effects, hospitalization or anesthesia. Our dynamic design includes several different types of coils, designed to target different parts of the brain, with a process tailored for each disorder.

Market Opportunity

-Brainsway’s vision is to be the global leader in non-invasive brain disorder therapy.
-1 in 6 adults in the U.S. suffers from a major depressive disorder episode during their lifetime.
-$64 billion were spent on prescription medications for the treatment of various brain disorders in 2014. The U.S depression therapeutics market is estimated at $15 billion.
-70% of the U.S. population carries health insurance plans that covers TMS treatment, for patients who fall to benefit from at least one prior antidepressant in the current episode*. Several studies, including one by Rush et al. in the 2006 American Journal of Psychiatry, found the number of patients who fall into this category to be around 50% of those treated.  *According to IMS Institutes for Health Informatics

Why Brainsway?

-Our treatment is non-invasive and has no systemic side effects.
-We have strong clinical backing, having participated in over 60 studies worldwide, resulting in 30 scientific publications.
-Brainsway Deep TMS is in use in numerous hospitals, private clinics and institutes worldwide, with over 6,000 patients treated to date.
-Our proprietary platform, covered by 7 family patents, is capable of treating a broad range of brain disorders.
-Brainsway has been cleared by the FDA for treating major depressive disorder. We also have 4 investigational device exemption (IDE) pivotal multi-center trials underway, with the goal of obtaining clearance for treating bipolar depression, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), and smoking addiction. We are also conducting clinical feasibility trials for treatment of Alzheimer’s disease, Parkinson’s disease, stroke, epilepsy and chronic pain.
-Brainsway is the only TMS manufacturer actively pursuing FDA clearance for indications other than depression.
-Our technology has received CE (European Conformity) clearances for treating major depressive disorder, OCD, PTSD, stroke after-effects, bipolar depression, schizophrenia, Parkinson’s disease, cigarette addiction, autism spectrum disorders, Asperger’s, multiple sclerosis and chronic pain in Europe.
-Studies have shown that Deep TMS has the potential to transiently increase the permeability of the blood-brain barrier. This may enable Brainsway to tap into the central nervous system (CNS) drug delivery market in the future.
-Brainsway is currently in the process of developing the first-of-its-kind multi-channel stimulator, which will enable synchronized activation of different brain networks to improve clinical efficacy.

Our Team

Brainsway is led by a new management team, with years of experience in the medical industry. Our team has a proven track record and is determined to achieve both our long- and short-term goals.

We are passionate about providing patients with cutting-edge solutions to help them take back control of their mental health, regain happiness and improve their quality of life.
-We have 70 employees, with direct operations in Israel and the U.S.

Financial Snapshot 2015

-Brainsway has been a public company since January 2007 (TASE:BRIN).
-Revenue growth: $3.4M in 2014 to $6.8M in 2015 (100%).
-2015 cash balance: $12M.

Note: The information presented herein is for investors only. Brainsway has currently been cleared only by the FDA for the treatment of MDD. Investigations into all other indications discussed herein are ongoing.

For more information contact:
Hadar Levy +972(0)54-569-9133
Hadarl@Brainsway.com

**Note:** The table and images are not included in the text representation.